Co-administration of glucose during nelfinavir and doxorubicin treatment in doxorubicin-resistant CML cells reduced nelfinavir-mediated sensitization to doxorubicin, further confirming the possible role of ATP-depletion in inhibition of P-gp and efflux of doxorubicin. The gene discussed is PGP; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.